title: Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors.
abstract: Psoriasiform eruptions are a classical adverse skin reaction of tumour necrosis factor (TNF)-α inhibitors. The aim of this study was to identify the association between the severity or pattern of psoriasiform reactions and the underlying disease. A retrospective study was conducted between January 2012 and May 2015. Adult patients who developed psoriasiform eruptions whilst being treated with TNFα inhibitors were included. For each patient, 3 independent blinded dermatologists graded twice the severity of the lesions according to 6 clinical psoriasiform eruption types. Inter- and intra-individual kappa tests were performed to evaluate the robustness of the scoring system. The association between severity score levels or the pattern of reactions and the underlying disease was assessed. The severity scoring system showed good inter- and intra-observer reproducibility. Women patients treated with TNFα inhibitors for inflammatory bowel diseases showed a higher risk of developing severe reactions with scalp and skin-fold involvement.
authors.affiliation: Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Saint-André Hospital, Bordeaux, France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Darrigade
authors.forename: Brigitte
authors.initials: B
authors.lastname: Milpied
authors.forename: Marie-Elise
authors.initials: ME
authors.lastname: Truchetet
authors.forename: Thierry
authors.initials: T
authors.lastname: Schaeverbeke
authors.forename: David
authors.initials: D
authors.lastname: Laharie
authors.forename: Frank
authors.initials: F
authors.lastname: Zerbib
authors.forename: Marie
authors.initials: M
authors.lastname: Beylot-Barry
authors.forename: Thomas
authors.initials: T
authors.lastname: Jouary
authors.forename: Alain
authors.initials: A
authors.lastname: Taïeb
authors.forename: Khaled
authors.initials: K
authors.lastname: Ezzedine
authors.forename: Julien
authors.initials: J
authors.lastname: Seneschal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001168:Arthritis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D003872:Dermatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012307:Risk Factors; D012536:Scalp Dermatoses / Q000139:chemically induced* / Q000473:pathology; D012720:Severity of Illness Index; D012737:Sex Factors; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha